NCT02472431View on ClinicalTrials.gov

Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Erectile DysfunctionImpotence, Vasculogenic
Interventions
OTHER

Intracavernosal administration of autologous ADRC

Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.

PROCEDURE

Liposuction

DEVICE

ADRC isolation

ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol

Trial Locations (2)

119991

I.M. Sechenov First Moscow State Medical University, Moscow

121359

"Federal State Budgetary Institution Central Clinical Hospital with Outpatient Health Center of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies", Moscow

All Listed Sponsors
collaborator

I.M. Sechenov First Moscow State Medical University

OTHER

lead

Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation

OTHER_GOV

NCT02472431 - Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Erectile Dysfunction | Biotech Hunter | Biotech Hunter